The European Medicines Agency's Pharmacovigilance Working Party (PhVWP) made the decision after the results of a meta-analysis on SSRIs and other antidepressants by the US Food and Drug Administration (FDA).
Although this review showed no increased risk on suicidality in adults taking antidepressants, younger patients did have higher odds of committing suicide.
As no clear difference was seen across the different antidepressant classes, the PhVWP has decided companies making all antidepressant products should include warnings on suicide, particularly on the increased risk for younger people and the need for close monitoring of patients.
The written guidelines need to be in place by the beginning of March.
In the UK, the only antidepressant that can be given to adolescents is flouxetine (Prozac) following an MHRA ruling in 2003.
Comment below and tell us what you think